Furthermore, tumor burden in the cohort of mice treated with Ad5/3-CXCR4-TIMP2, the armed CRAd, was significantly less when compared to the tumor burden in mice treated with both Ad5/3-CXCR4 and the unarmed CRAd (p<0.01; Fig. 2B). Here, CXCR4 is linked to neoplasm.